Cargando…

A Patient‐Centric Model for Discontinuation of a Single‐Sourced Approved Drug

Detalles Bibliográficos
Autores principales:	Caplan, Arthur, Teagarden, J. Russell, Bacher, Hans Peter, Jarvis, Michael F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766784/ https://www.ncbi.nlm.nih.gov/pubmed/30977518 http://dx.doi.org/10.1002/cpt.1411

Ejemplares similares

A zebrafish-centric approach to antiepileptic drug development
por: Baraban, Scott C.
Publicado: (2021)

Diversity and Inclusion in Drug Development: Rethinking Intrinsic and Extrinsic Factors with Patient Centricity
por: Venkatakrishnan, Karthik, et al.
Publicado: (2021)

An open science pathway for drug marketing authorization—Registered drug approval
por: Naudet, Florian, et al.
Publicado: (2021)

A Content-Centric Organization of the Genetic Code
por: Yu, Jun
Publicado: (2007)

Challenges and opportunities for improving access to approved neonatal drugs and devices
por: Lewis, Tamorah, et al.
Publicado: (2022)

Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness
por: Abdin, Ahmad Yaman, et al.
Publicado: (2023)

Conditional early approval for new drug applications in Japan: Current and emerging issues
por: Tanaka, Mototsugu, et al.
Publicado: (2023)

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
por: Brennan, Paul N., et al.
Publicado: (2023)

Chloe’s Law: A Powerful Legislative Movement Challenging a Core Ethical Norm of Genetic Testing
por: Caplan, Arthur L.
Publicado: (2015)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Health disparities and clinical trial recruitment: Is there a duty to tweet?
por: Caplan, Arthur, et al.
Publicado: (2017)

Getting serious about the challenge of regulating germline gene therapy
por: Caplan, Arthur
Publicado: (2019)

Operationalizing Stakeholder Engagement Through the Stakeholder-Centric Engagement Charter (SCEC)
por: Martínez, Jenny, et al.
Publicado: (2022)

Science in the fight to uphold the rights of children
por: Caplan, Arthur L., et al.
Publicado: (2018)

The Actress, the Court, and What Needs to Be Done to Guarantee the Future of Clinical Genomics
por: Caplan, Arthur L.
Publicado: (2013)

Towards reperfusion-centric preclinical stroke research: outside the box of “reperfusion injury”
por: Kuan, Chia Yi, et al.
Publicado: (2015)

Motivating Pulse-Centric Eating Patterns to Benefit Human and Environmental Well-Being
por: Didinger, Chelsea, et al.
Publicado: (2020)

Managing Heterogeneity in Prescription Drug Coverage Policies
por: Teagarden, J. Russell
Publicado: (2014)

What Is a Digital Twin? Experimental Design for a Data-Centric Machine Learning Perspective in Health
por: Emmert-Streib, Frank, et al.
Publicado: (2022)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

An in-silico evaluation of COVID-19 main protease with clinically approved drugs
por: Tachoua, Wafa, et al.
Publicado: (2020)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Enhancing Patient Centricity and Advancing Innovation in Clinical Research with Virtual Randomized Clinical Trials (vRCTs)
por: Yaakov, Raphael A., et al.
Publicado: (2021)

Quality by Design risk assessments supporting approved antibody products
por: Kelley, Brian
Publicado: (2016)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Japan's COVID‐19 treatment strategy: An examination of approved oral medications
por: Higuchi, Yuka, et al.
Publicado: (2023)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Chimeric Humanized Vasculature and Blood: The Intersection of Science and Ethics
por: Garry, Daniel J., et al.
Publicado: (2020)

The FDA-Approved Essure Device Counseling Order Fails to Promote Patient Empowerment
por: Gunn, Christine M., et al.
Publicado: (2019)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation
por: Jauhar, Sameer, et al.
Publicado: (2023)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Research for Improving the Chance of Success of Drug Design and Discovery
por: Mao, Fei, et al.
Publicado: (2016)

On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
por: Pappin, Jessie, et al.
Publicado: (2022)

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2023)

Premarket Approval Through the 510(k) Process: Lessons from the Translation Process of Magnetic Resonance Elastography
por: Aponte Ortiz, Jaime A., et al.
Publicado: (2018)

Approved gene therapies in Australia: coming to a store near you
por: Mallik, Shreyashee, et al.
Publicado: (2022)

Marine Microbiome as a Source of Antimalarials
por: McCarthy, Peter J., et al.
Publicado: (2019)

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
por: Trias, Esteve, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gm4af0uii44ubigja8v6n8ini1